Related Experiment Videos
Left ventricular reconstruction: Early and late results
Lynda L Mickleborough1, Naeem Merchant, Joan Ivanov
1University of Toronto, Ontario, Canada. l.mickleborough@on.aibn.com
The Journal of Thoracic and Cardiovascular Surgery
|June 30, 2004
Summary
Left ventricular reconstruction improves outcomes for patients with coronary disease and poor heart function. This surgical option offers good symptom control, excellent survival, and freedom from sudden death.
Area of Science:
- Cardiovascular Surgery
- Cardiac Reconstruction
- Heart Failure Management
Background:
- Coronary artery disease frequently leads to impaired left ventricular function.
- Ventricular reconstruction is a surgical consideration for patients with akinetic or dyskinetic segments and wall thinning.
- Optimal patient selection and surgical techniques for ventricular reconstruction remain areas of investigation.
Purpose of the Study:
- To evaluate the outcomes of ventricular reconstruction in patients with coronary disease and poor left ventricular function.
- To assess the efficacy of ventricular reconstruction using wall thinning as a primary selection criterion.
Main Methods:
- Prospective data collection from 285 patients undergoing ventricular reconstruction.
- Surgical techniques included modified linear closure, septoplasty, and coronary artery bypass grafting.
- Concomitant procedures involved ablation for ventricular tachycardia and mitral valve interventions.
Main Results:
- Low operative mortality (2.8%) with significant perioperative support.
- Mean follow-up of 63 months demonstrated good long-term survival (92% at 1 year, 62% at 10 years).
- Symptom improvement (67%) and increased ejection fraction (average 10% increase) were observed postoperatively.
Conclusions:
- Ventricular reconstruction, guided by wall thinning criteria, is a viable option for selected patients.
- The procedure offers low operative risk, effective symptom management, and favorable long-term survival.
- This approach should be considered for patients with coronary disease, reduced ejection fraction, and ventricular wall thinning.